New
Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →
Help us improve your experience. Please confirm your investor type:
ETF What's Up
Don’t Miss a Move in the ETF Market
Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.
IDNA ETF · iShares Genomics Immunology and Healthcare ETF
The IDNA Exchange Traded Fund (ETF) is provided by iShares. It is built to track an index: NYSE FactSet Global Genomics and Immuno Biopharma Index. The IDNA ETF provides physical exposure, so by buying it you actually own parts of all the 51 underlying holdings. This share class generates a stream of income by distributing dividends.
Last update Yesterday at 1:30 PM UTC
LIVE
CLOSED
This fund is part ofBioTech & Genomics1M perf.-1.33%
Last price
$28.78
1M perf.
-0.56%
1M flows
+€5.1M
AuM
€130M
E/R
0.47%
Rating
ESG Consensus®
IDNA
$28.78
Performance & flows
Segment for quartile rank
December 15, 2025 → March 13, 2026
Create a free account to view the flows graph
IDNA
$28.81
+9.39%
BioTech & Genomics
-5.41%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | -0.56%  | +9.39% | +34.26%  | +28.81% | -37.05% | -7.29% | +10.03% | +10.03% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
More details
NAV
3/13/2026
$28.81
1D NAV change
-0.22%
Dividend policy
Replication method
Direct (Physical)
Replication model
Full replication
No. of holdings
51
Inception date
6/11/2019
Jurisdiction
United States
Distribution
United States
Legal structure
Unit Investment Trust
Base currency
USD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Product type
Asset class
Factors
N/A
Investment strategy
The iShares Genomics Immunology and Healthcare ETF seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.
Enterprise Fund page features include:
Legal documents
Powerful buy-list integration
Fund data exports
Advanced risk metrics
Advanced replication analysis
Advanced exposure look-through
Upload your own internal metrics
Custom data feature
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSimilar ETFs in your region
XDNA
1M perf.
+0.35%
E/R
0.44%
2B78
1M perf.
-5.22%
E/R
0.4%
LIV
1M perf.
-0.93%
E/R
0.75%
PJP
1M perf.
-6.91%
E/R
0.57%
TMED
1M perf.
+0.34%
E/R
0.44%
Advertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | +9.39% | +34.26% | +28.81% | -37.05% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
Built for professionals: access exclusive risk metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseExposure
Countries
USA
62.28%
France
8.30%
Japan
6.25%
Switzerland
6.03%
Germany
4.93%
United Kingdom
3.86%
Denmark
3.80%
China
2.13%
Unavailable
0.15%
Other
2.28%
Sectors
Health Care
93.20%
Unavailable
6.80%
Diversification
Total weight of top 15 holdings out of 51
Top 15 holdings
Data as of January 31, 2026
MODERNA INC
BAYER AG
REVOLUTION MEDICINES INC
BIONTECH SE ADR
TAKEDA PHARMACEUTICAL
ROCHE
IPSEN PROMESSES
MERCK & CO INC
Create a free account to view top holdings
GSK PLC
VERTEX PHARMACEUTICALS
REGENERON PHARMACEUTICALS
GENMAB
INCYTE
EXELIXIS
SANOFI SA
Create a free account to view top holdings
Built for professionals: access exclusive exposure metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSustainability
Integrates ESG criteria
No
SDG
ESG Consensus® by Conser
Data as of December 31, 2025
MethodologyOur partner Conser gathers the industry's consensus on the business practices of the underlying holdings. We have computed the following metrics about IDNA ETF's sustainability, based on their methodology.
ESG Consensus®
ESG Consensus® is based on the Final Sustainability Grade, which itself consists of 10 grades. Our partner Conser calculates the exact grade, based on market intelligence, using their proprietary ESG Consensus® methodology.
IDNA’s has a Final Sustainability Grade of either B+, B, or B-.
A+
A
A-
B+
B
B-
C+
C
C-
D
This fund’s exact Final Sustainability Grade is available in Trackinsight Enterprise.
Learn more about Trackinsight EnterpriseHoldings review
84.91% of holdings have positive scoring
15.23% of holdings have negative scoring
11.05%
58.29%
15.57%
9.16%
Consensus levels
Strong
Medium
Weak
Built for professionals: access exclusive sustainability metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseReplication
Trackinsight replication rating:
Replication quality
Calculated over 12m, as of February 27, 2026
Tracking error
Tracking difference
Replication information
Index
NYSE FactSet Global Genomics and Immuno Biopharma Index NTR - USD
Index ticker
NYFSGIBN Index
Index dividend policy
NTR
Replication method
Replication model
Built for professionals: access exclusive replication metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseIssuer
iShares
iShares ID Card
Number of funds
1720
Total AuM
€4.9T
Expense ratio range
0.03% - 1.51%
Average expense ratio
0.285%
Top 5 funds by iShares
| AuM | ||
|---|---|---|
IVV | iShares Core S&P 500 ETF | €604.11B |
IEFA | iShares Core MSCI EAFE ETF | €145.9B |
AGG | iShares Core U.S. Aggregate Bond ETF | €120.51B |
IEMG | iShares Core MSCI Emerging Markets ETF | €118.19B |
CSSPX | iShares Core S&P 500 UCITS ETF | €112.42B |
Frequently asked questions about IDNA
What does iShares Genomics Immunology and Healthcare ETF, IDNA, invest in?
IDNA is a Passive ETF. This ETF provides exposure to Global Equities.
Which benchmark or index does IDNA replicate?
IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index NTR - USD, through a full replication replication method.
What is the Total Expense ratio (TER) of IDNA?
IDNA carries a total expense ratio (TER) of 0.47%, indicating the annual cost for holding the fund.
When was IDNA launched?
IDNA was introduced to the market on June 11, 2019. It trades on United States
Who is the ETF issuer of IDNA?
iShares Genomics Immunology and Healthcare ETF, IDNA, is provided by iShares. Learn more about iShares here.
What is the current assets under management (AUM) of IDNA?
IDNA oversees €130M in assets as of March 13, 2026.
How has IDNA performed lately?
Based on data from March 13, 2026, IDNA returned -0.56% over the past month, 9.39% over the last three months and 10.03% year-to-date.
What are the latest inflows or outflows for IDNA?
As of March 13, 2026, IDNA recorded net flows of +€5.1M over the last month and +€5.1M year-to-date.
Does IDNA distribute dividends?
IDNA follows a distributing dividend policy, meaning it pays out income to investors. As of March 13, 2026, its 12-month trailing yield was 1.07%.
What are the main country or region exposures of IDNA?
As of January 31, 2026, IDNA has significant geographic allocations in USA, France and Japan.
In which sector or theme does IDNA invest in?
As of January 31, 2026, IDNA focuses largely on Health Care.
How many securities does IDNA hold and how diversified is it?
As of January 31, 2026, IDNA holds 51 positions in its portfolio, with 62.44% of assets concentrated in its top 15 holdings.
What are the main positions in IDNA?
As of January 31, 2026, IDNA top three holdings include MODERNA INC, BAYER AG and REVOLUTION MEDICINES INC.
What is the base currency of IDNA?
The base currency of IDNA is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
